N4 PHARMA PLC — Director's Dealing 2016

Jan 19, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2412M

Evgen Pharma PLC

19 January 2016

For immediate release                                                                                                                 19 January 2016

Evgen Pharma plc

("Evgen" or the "Company")

Director Share Purchases

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 18 January 2016, certain Directors purchased an aggregate of 136,000 ordinary shares of 0.25 pence each at a price of 22.5 pence per share.  The Directors participating in the purchase and their interests in the share capital of the Company following the purchase are as follows:

Director	Number of Ordinary Shares pursuant to Directors' dealing	Holding following Directors' dealing	Percentage of Ordinary Shares following Directors' dealing
Barry Clare	40,000	940,108	1.3%
Stephen Franklin	56,000	1,375,200	1.9%
John Bradshaw	40,000	40,000	0.1%

Enquiries:

Evgen Pharma plc	+44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
www.evgen.com
Northland Capital Partners Limited	+44 (0) 20 7382 1100
Matthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance)
John Howes (Corporate Broking)
Buchanan	+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.  Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park.  For further information please visit www.evgen.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBPMRTMBABBFF

//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'XqtPtFSn-gJf_qOdLZhu3GCI5XWQ4mEAap-Z3WczCwG7c2Q7liJt_utsxBO1vKgvgXQ0hIGevHdJetoP9b-1mEKqkupHvAgKCAu_aHg_Pg41:3_beWQDvXEqlusCcPQdLZ4RrBkeFzc6ivjZOKLtjEPco544DPCPPNbUxQwb0WfRZ6IXE8cFM7S7ZlaTbo4EOqIDdnxAVr9SP5C2K5FIN-QE1'}});//]]>